AUTHORS
Kai Shen, MD, Jin Rao, MD2, Xiaoli Fei, MD3, Juecai Chen, MD4, Chenlu Yang, PhD5, Baozhu Luo, MD6, Jiazhuo Liu7, Ting MD, PhD Niu, MD, PhD8
AFFILIATIONS
1 West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Affiliated Hospital of Chengdu University, Chengdu, China
3 The First People's Hospital of Chengdu, Chengdu, China
4 The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
5 West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 West China Hospital, Sichuan University, Chengdu, Sichuan, China
7 West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 West China Hospital, Sichuan University, Chengdu, Sichuan, China
ABSTRACT
Background
Cancer treatment–induced thrombocytopenia (CTIT) is a frequent adverse effect of antineoplastic therapies. Current management options include recombinant human interleukin-11 (rhIL-11), recombinant human thrombopoietin (rhTPO), and oral thrombopoietin receptor agonists (TPO-RAs). However, a subset of patients develops refractory CTIT despite the discontinuation of anti-cancer treatment and thrombopoietic support. The pathogenesis of refractory CTIT is often multifaceted, making its etiological diagnosis and management particularly challenging. Romiplostim N01, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein and the first romiplostim biosimilar approved in China, features an extended half-life and lacks endogenous TPO homologous sequences, thereby minimizing the risk of cross-reactivity and neutralizing antibody formation. These properties position it as a potentially effective therapeutic option for patients with refractory CTIT.
Aims
To evaluate the real-world efficacy of Romiplostim N01 in cancer patients with refractory CTIT.
Methods
This was a retrospective, multi-center study. We enrolled cancer patients with refractory CTIT who had received at least one prior line of thrombopoietic agent before initiating Romiplostim N01. Refractory CTIT was defined as persistent grade ≥2 thrombocytopenia (PLT <75×10?/L) after 30 days since the end of last anticancer therapy. All patients received at least one subcutaneous dose of Romiplostim N01 (a fixed dose of 250 µg for the first injection). Demographic characteristics, tumor types, anticancer regimens, prior thrombopoietic therapies, hematologic responses, and adverse events were extracted from hospital information systems. The primary endpoint was the response rate, defined as meeting any of the following criteria without platelet transfusion: (1) PLT increase ≥50×10?/L, (2) PLT elevation to ≥2 times baseline, or (3) PLT ≥100×10?/L. Patients failing to respond after three consecutive doses were classified as non-responders.
Results
Between June 1, 2024, and May 30, 2026, 30 patients with refractory CTIT from 4 centers were included. The median age was 65 years (range, 22–76), and 67.7% were male. Prior anticancer regimens included chemotherapy (48.4%), targeted therapy (25.8%), immunotherapy (19.4%), and radiotherapy (3.2%). Tumor types encompassed colorectal cancer(n=6), lung cancer(n=4), breast cancer (n=3), multiple myeloma (n=3), lymphoma (n=3), nasopharyngeal cancer(n=2), pancreatic cancer (n=2), and eight other miscellanious malignancies (one each). The median baseline PLT was 23×10?/L (range, 7–70). Anemia was present in 65% of patients, with a median hemoglobin of 106 g/L (range, 72–163). Bone marrow aspiration/biopsy, performed in 16 patients, revealed hypocellularity in 4 (25%) and reduced megakaryocytes in 1 (6%). Refractory CTIT developed after a median of 4.5 cycles (range, 1–15) of anticancer regimens. Patients had received a median of 2 prior lines (range, 1–4) of thrombopoietic therapy; 14 patients (46.7%) had been treated with both TPO-RA and rhTPO before Romiplostim N01. The response rate after the first 250µg dose was 63.3% (19/30), with a median peak PLT of 71×10?/L (range, 11–380). Among non-responders after the first dose, 45.5% (5/11) responded after the second dose, and 33.3% (2/6) responded after the third, yielding an overall response rate (ORR) of 86.7% (26/30). In the subset refractory to both TPO-RA and rhTPO, the first-dose response rate was 50.0% (7/14), and the ORR reached 85.7% (12/14) after three doses. No venous thromboembolic events or major bleeding episodes were documented within the first month following the initial dose.
ConclusionRefractory CTIT remains a clinical challenge due to its complex pathophysiology. Our real-world data demonstrate that subcutaneous Romiplostim N01 is highly effective in cancer patients with refractory CTIT, including those who had failed both TPO-RA and rhTPO. These findings suggest that Romiplostim N01 with a fixed initial dose of 250 µg may serve as a potent and safe salvage therapy for this difficult-to-treat population.
DISCLOSURES
Kai Shen, MD: No relevant conflicts of interest to declare.